Effective HIV prevention: The indispensable role of social science

Journal of the International AIDS Society

Volumn 15, Issue 2, 2012, Pages

  Kippax, Susan ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Behaviour change; Community capacity; Effectiveness; HIV prevention; Social dimensions; Structural drivers

Indexed keywords

MICROBICIDE;

ANAL INTERCOURSE; BEHAVIOR CHANGE; CIRCUMCISION; CONDOM; CRIMINAL LAW; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NOTE; PRIORITY JOURNAL; PROSTITUTION; SEXUAL TRANSMISSION; SEXUALITY; SOCIAL ENVIRONMENT; SOCIOLOGY; STIGMA; ARTICLE; BEHAVIOR THERAPY; HEALTH SERVICES RESEARCH; INFECTION CONTROL; METHODOLOGY;

BEHAVIOR THERAPY; COMMUNICABLE DISEASE CONTROL; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; SOCIAL SCIENCES;

EID: 84867475486     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.15.2.17357     Document Type: Note

References (64)

1. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. The Lancet. 2008;372:845-59.
2. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. The Lancet. 2008;372:669-84.
3. Rao Gupta G, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. The Lancet. 2008;372:764-75.
4. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. The Lancet. 2008;372:585-99.
5. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med. 2011;154:1-7.
6. Lancet Editorial. HIV treatment as prevention - it works. The Lancet. 2011;377:1719.
7. Lancet Editorial. Treatment as prevention for HIV. Lancet Infect Dis. 2011;1:651.
8. Fassin D. When bodies remember. Berkeley: University of California Press; 2007.
9. Aral SO, Peterman TA. Do we know the effectiveness of behavioural interventions? The Lancet. 1998;351 Suppl 111:33-6.
10. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV prevention. AIDS. 2010;24 Suppl 4:S70-80.
11. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, et al. Reassessing HIV prevention. Science. 2008;320:749-50.
12. Aggleton P. "Just a snip"? A social history of male circumcision. Reprod Health Matters. 2007;15:15-21.
13. Niang CI, Boiro H. "You can also cut my finger!": social construction of male circumcision in West Africa. A case study of Senegal and Guinea-Bissau. Reprod Health Matters. 2007;15:22-32.
14. Weiss H, Halperin D, Bailey RC, Hayes RJ, Schmid G, Hankins CA. Male circumcision for HIV prevention: from evidence to action? AIDS. 2008;22:567-74.
15. Stanger-Hall KF, Hall DW. Abstinence-only education and teen pregnancy rates: why we need comprehensive sex education in the U.S. PLoS ONE. 2011; 6(10):e24658. doi:10.171/journal.pone.0024658
16. Kippax S, Race K. Sustaining safe practice: twenty years on. Soc Sci Med. 2003;57:1-12.
17. Hallett TB, Aberle-Grasse J, Bello G, Boulos LM, Cayemittes MP, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect. 2006;82 Suppl 1:1-8.
18. Cameron E. Stigma, human rights, testing and treatment - time for action, Ruben Sher Memorial Lecture, 26 November 2009. Southern African J HIV Med. 2010 April:6-18.
19. Schwartlander B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/ AIDS. The Lancet. 2011;377:2031-41.
20. Auerbach JD, Parkhurst JO, Caceres C. Addressing social drivers of HIV/AIDS for the long-term response: conceptual and methodological considerations. Global Public Health. 2011;6(S3):S293-309.
21. Friedman SR, Rossi D, Braine N. Theorizing "big events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy. 2009;20:283-91.
22. Wodak A, Cooney A. Do needle syringe programmes reduce HIV infection among injecting drug users: a comprehensive review of international evidence. Substance Use & Misuse. 2006;41:777-813.
23. Mahajan AP, Sayles JN, Patel VA, Remien RH, Sawires SR, Ortiz DJ, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS. 2008;22 Suppl 2:S67-79.
24. Mykhalovskiy E. The problem of "significant risk": exploring the public health impact of criminalising HIV non-disclosure. Soc Sci Med. 2011;73: 668-75.
25. Hanenberg RS, Rojanapithayakorn W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline in sexually transmitted diseases. The Lancet. 1994;344:243-5.
26. Low-Beer D, Stoneburner R. Behaviour and communication change in reducing HIV: is Uganda unique? African J AIDS Res. 2003;2(1):9-12.
27. Stoneburner R, Low-Beer D. Population-level HIV declines and behavioural risk avoidance in Uganda. Science. 2004;304:714-8.
28. Thornton RJ. Unimagined community: sex, networks, and AIDS in Uganda and South Africa. Berkeley: University of California Press; 2008.
29. Bowtell W. Australia's response to HIV/AIDS 1982-2005. Report prepared for Research and Dialogue Project on Regional Responses to the spread of HIV/ AIDS in East Asia organised by the Japan Center for International Exchange and the Friends of the Global Fund to Fight AIDS Tuberculosis and Malaria (Japan). Sydney: Lowy Institute for International Policy; 2005.
30. Mindel A, Kippax S. A national strategic approach to improving the health of gay and bisexual men: experience in Australia. In: Aral SO, Fenton K, editors, The new public health and STD/HIV prevention: personal, public and health system approaches. (in press)
31. Friedman SR, de Jong W, Rossi D, Touze G, Rockwell R, Des Jarlais DC, et al. Harm reduction theory: Users' culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users' groups. Int J Drug Policy. 2007;18:107-17.
32. Kippax S. Understanding and integrating the structural and biomedical determinants of HIV-infection: a way forward for prevention. Current Opinion in HIV and AIDS. 2008;3:489-94.
33. Kippax S, Crawford J, Davis M, Rodden P, Dowsett GW. Sustaining safe sex: a longitudinal study of a sample of homosexual men. AIDS. 1993;7:257-63.
34. Mao L, Kippax S, Holt M, Prestage G, Zablotska-Manos I, de Wit J. Rates of condom and non-condom based anal intercourse practices among homosexually active men in Australia: deliberate HIV risk reduction? Sex Transm Infect. 2011;87:489-93.
35. Mao L, Crawford J, Hospers H, Prestage G, Grulich A, Kaldor J, et al. 'Serosorting' in casual anal sex of HIV-negative gay men is noteworthy and is increasing in Sydney, Australia. AIDS. 2006;20:1204-6.
36. Van de Ven P, Kippax S, Crawford J, Rawstorne P, Prestage G, Grulich A, et al. In a minority of gay men, sexual risk practice indicates strategic positioning for perceived risk reduction rather than unbridled sex. AIDS Care. 2002;14:471-80.
37. Van de Ven P, Mao L, Fogarty A, Rawstorne P, Crawford J, Prestage G, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS. 2005;19:179-84.
38. Poynten IM, Jin F, Mao L, Prestage G, Kippax S, Kaldor J, et al. Non-occupational post-exposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS. 2009;23:1119-26.
39. Zablotska I, Prestage G, Middleton M, Wilson D, Grulich A. Contemporary HIV diagnoses trends in Australia can be predicted by trends in unprotected anal intercourse among gay men. AIDS. 2010;24:1955-8.
40. Sullivan P, Hamouda O, Delpech V, Geduld JE, Prejean J, Semaille C, et al. Re- emergence of the HIV epidemic among men who have sex with men in North America, Europe and Australia 1996-2005. Ann Epidemiol. 2009;19:423-31.
41. Stall R, Duran L, Wisniewski S, Friedman MS, Marshal MM, McFarland W, et al. Running in place: implications for HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries. AIDS & Behav. 2009;13:615-29.
42. Kippax S. Sexual health interventions are unsuitable for experimental evaluation. In: Stephenson JM, Imrie J, Bonell C, editors. Effective sexual health interventions: issues in experimental evaluation. Oxford: Oxford University Press; 2003. p. 17-34.
43. Race K. Configurations of responsibility: the performativity of framing devices in dynamics of HIV transmission. Paper presented at 1st International HIV Social Sciences and Humanities Conference: Locating the Social; 2011 June 11-13; Durban, South Africa.
44. Gregson S, Garnett GP, Nyamukupa CA, Hallett TB, Lewis JJ, Mason PR, et al. HIV decline associated with behaviour change in eastern Zimbabwe. Science. 2006;311:664-6.
45. Halperin DT, Mugurungi O, Hallett TB, Muchini B, Campbell B, Magure T, et al. A surprising prevention success: why did the HIV epidemic decline in Zimbabwe? PLoS Med. 2011;8(2):e1000414.
46. Global HIV Prevention Working Group. New Approaches to HIV Prevention: accelerating research and ensuring future access. USA: Gates Foundation/ Kaiser Family Foundations; 2006. Available from: www.gatesfoundation.org
47. Global HIV Prevention Working Group. Bringing HIV prevention to scale: an urgent global priority. USA: Gates Foundation/Kaiser Family Foundation; 2007. Available from: www.globalhivprevention.org
48. Global HIV Prevention Working Group. Behavior change and HIV prevention: Re(Considerations) for the 21st Century. USA: Gates Foundation/ Kaiser Family Foundation; 2008. Available from: www.globalhivprevention.org
49. Kippax S, Reis E, de Wit J. Two sides to the HIV prevention coin: efficacy and effectiveness. AIDS Educ Prev. 2011;23:393-6.
50. Vernazza P, Hirschel B, Bernasconi E. Les personnes seropositives suivant un TAR efficace ne transmettant pas le VIH pat voie sexuelle. Bulletin de Medicins Suisses. 2008;89:5.
51. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early anti-retroviral therapy. New Engl J Med. 2011;365:493-505.
52. Montaner JSG, Lima VD, Barios R, Yip B,Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new diagnoses in British Columbia, Canada: a population-based study. The Lancet. 2010;376:532-9.
53. Cohen MS, Fidler S. HIV prevention : where are we now and where are we going? Current Opinion in HIV and AIDS. 2010;5:265-8.
54. Granich RM, Gilks CF, Dye C, de Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for the elimination of HIV transmission: a mathematical model. The Lancet. 2009;373:48-57.
55. Garnett GP, Baggaley R. Treating our way out of the HIV pandemic: could we, would we, should we? The Lancet. 2009;373:9-11.
56. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS. 2010;24:729-35.
57. Ambrosioni J, Calmy A, Hirschel B. HIV treatment for prevention. J Int AIDS Soc. 2011; 14:28. doi:10.1186/1758-2652-14-28
58. Kippax S, Stephenson N. Beyond the distinction between biomedical and social dimensions of HIV: prevention through the lens of a social public health. Am J Public Health. 2012;102:789-99.
59. Cates W. HPTN 052 and the future of HIV treatment and prevention. The Lancet. 2011;378:224-5.
60. Epstein H, Morris M. HPTN 052 and the future of HIV treatment and prevention. The Lancet. 2011;378:225.
61. Seale A, Lazarus JF, Grubb I, Fakoya A, Atun R. HPTN 052 and the future of HIV treatment and prevention. The Lancet. 2011;378:226.
62. Stephenson N. A social public health. Am J Public Health. 2011; 101(7):1159. doi:10.2105/AJPH.2011.300240
63. Low-Beer D. The alphabet of AIDS prevention. The Lancet. 2004;364: 19-20.
64. Rosengarten M. HIV interventions: biomedicine and the traffic between information and flesh. Seattle, WA: University of Washington Press.